Post-earnings recap
Reported
Tue, Feb 11, 2025
EPS actual
$-0.44
EPS est.
$-1.15
EPS surprise
+61.84%
1-day move
+0.53%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that CRISPR Therapeutics exceeded expectations on EPS, which contributed to a slight increase in stock price. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may view the EPS beat as a positive sign, but the absence of detailed financial metrics and future outlook could temper enthusiasm.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | +61.84% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS performance, highlighting ongoing efforts in their research and development. They emphasized a commitment to their long-term goals.
We are pleased with our progress in the quarter despite the challenges faced.
Our focus remains on advancing our pipeline and delivering value to patients.